Jacobs Levy Equity Management, Inc Century Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.46 - $4.05 $697,060 - $1.15 Million	-283,358 Reduced 96.4%	10,583 $26,000
Q1 2024 May 15, 2024	BUY	$3.19 - $5.32 $615,398 - $1.03 Million	192,915 Added 190.96%	293,941 $1.23 Million
Q4 2023 Feb 14, 2024	SELL	$1.28 - $3.32 $89,927 - $233,249	-70,256 Reduced 41.02%	101,026 $335,000
Q3 2023 Nov 16, 2023	SELL	$2.0 - $3.23 $23,884 - $38,572	-11,942 Reduced 6.52%	171,282 $342,000
Q2 2023 Aug 14, 2023	SELL	$2.91 - $3.53 $405,269 - $491,616	-139,268 Reduced 43.18%	183,224 $578,000
Q1 2023 May 15, 2023	BUY	$3.4 - $5.11 $674,886 - $1.01 Million	198,496 Added 160.08%	322,492 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$4.84 - $11.58 $600,140 - $1.44 Million	123,996 New	123,996 $636,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $74.2M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.